Prolactin promotes cartilage survival and attenuates inflammation in inflammatory arthritis

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3902-3913

  Adań, Norma ^a   Guzmán Morales, Jessica ^a   Ledesma Colunga, Maria G ^a   Perales Canales, Sonia I ^a   Quintanar Stéphano, Andrés ^b   López Barrera, Fernando ^a   Méndez, Isabel ^a   Moreno Carranza, Bibiana ^a   Triebel, Jakob ^a   Binart, Nadine ^c   Martińez De La Escalera, Gonzalo ^a   Thebault, Stéphanie ^a   Clapp, Carmen ^a  

^a INSTITUTO DE NEUROBIOLOGÍA   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE AGUASCALIENTES   (Mexico)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GAMMA INTERFERON; INTERLEUKIN 1BETA; JANUS KINASE 2; MESSENGER RNA; PROLACTIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NITRIC OXIDE; PROLACTIN RECEPTOR; STAT3 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE EROSION; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DEATH; DISEASE ACTIVITY; GENE INDUCTION; HYPERPROLACTINEMIA; INFLAMMATION; INTERFERON PRODUCTION; JOINT SWELLING; KNEE; MOUSE; MULTIPLE SCLEROSIS; NICK END LABELING; NONHUMAN; PAIN; PANNUS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ARTICULAR CARTILAGE; CELL CULTURE; KNOCKOUT MOUSE; LEWIS RAT; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; CYTOKINES; DOPAMINE ANTAGONISTS; HALOPERIDOL; JANUS KINASE 2; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE; PROLACTIN; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, PROLACTIN; STAT3 TRANSCRIPTION FACTOR;

EID: 84883492086     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69485     Document Type: Article

References (80)

1. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-442. (Pubitemid 46834849)
2. Schuerwegh AJ, et al. Influence of pro-inflammatory (IL-1 alpha, IL-6, TNF-alpha, IFN-gamma) and anti-inflammatory (IL-4) cytokines on chondrocyte function. Osteoarthritis Cartilage. 2003;11(9):681-687. (Pubitemid 37045687)
3. Goggs R, et al. Apoptosis and the loss of chondrocyte survival signals contribute to articular cartilage degradation in osteoarthritis. Vet J. 2003;166(2):140-158. (Pubitemid 37554969)
4. Christodoulou C, Choy EH. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med. 2006;6(1):13-19.
5. Keffer J, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10(13):4025-4031. (Pubitemid 21905432)
6. Polzer K, Schett G, Zwerina J. The lonely death: chondrocyte apoptosis in TNF-induced arthritis. Autoimmunity. 2007;40(4):333-336. (Pubitemid 46845533)
7. Kim HA, Song YW. Apoptotic chondrocyte death in rheumatoid arthritis. Arthritis Rheum. 1999;42(7):1528-1537. (Pubitemid 30265612)
8. Yatsugi N, et al. Apoptosis of articular chondrocytes in rheumatoid arthritis and osteoarthritis: correlation of apoptosis with degree of cartilage destruction and expression of apoptosis-related proteins of p53 and c-myc. J Orthop Sci. 2000;5(2):150-156. (Pubitemid 30241771)
9. Lotz M. Cytokines in cartilage injury and repair. Clin Orthop Relat Res. 2001;(391 suppl):S108-S115. (Pubitemid 32954017)
10. Lo MY, Kim HT. Chondrocyte apoptosis induced by collagen degradation: inhibition by caspase inhibitors and IGF-1. J Orthop Res. 2004;22(1):140-144. (Pubitemid 38040032)
11. Andreas K, et al. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther. 2008;10(1):R9.
12. Macotela Y, et al. Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin. J Cell Sci. 2006;119(pt 9):1790-1800. (Pubitemid 43811005)
13. Zermeno C, et al. Prolactin inhibits the apoptosis of chondrocytes induced by serum starvation. J Endocrinol. 2006;189(2):R1-R8.
14. Ogueta S, et al. Prolactin is a component of the human synovial liquid and modulates the growth and chondrogenic differentiation of bone marrow-derived mesenchymal stem cells. Mol Cell Endocrinol. 2002;190(1-2):51-63. (Pubitemid 34462051)
15. Rovensky J, et al. Hormone concentrations in synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(3):292-296. (Pubitemid 40823535)
16. Nagafuchi H, et al. Prolactin locally produced by synovium infiltrating T lymphocytes induces excessive synovial cell functions in patients with rheumatoid arthritis. J Rheumatol. 1999;26(9):1890-1900. (Pubitemid 30007054)
17. Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res. 2002;57:435-455.
18. Wu GJ, et al. Nitric oxide from both exogenous and endogenous sources activates mitochondria-dependent events and induces insults to human chondrocytes. J Cell Biochem. 2007;101(6):1520-1531.
19. Teixeira CC, et al. Phosphate-induced chondrocyte apoptosis is linked to nitric oxide generation. Am J Physiol Cell Physiol. 2001;281(3):C833-C839.
20. DaSilva L, et al. Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580. Mol Cell Endocrinol. 1996;117(2):131-140. (Pubitemid 26118927)
21. Suemoto H, et al. Trps1 regulates proliferation and apoptosis of chondrocytes through Stat3 signaling. Dev Biol. 2007;312(2):572-581. (Pubitemid 350183980)
22. Siddiquee K, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007;104(18):7391-7396. (Pubitemid 47185916)
23. Adler RA. The anterior pituitary-grafted rat: a valid model of chronic hyperprolactinemia. Endocr Rev. 1986;7(3):302-313.
24. Schuff KG, et al. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest. 2002;110(7):973-981.
25. Kapur S, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. (Pubitemid 30191189)
26. Cai X, et al. The comparative study of Sprague-Dawley and Lewis rats in adjuvant-induced arthritis. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(2):140-147. (Pubitemid 43742439)
27. Neidhart M, Fluckiger EW. Hyperprolactinaemia in hypophysectomized or intact male rats and the development of adjuvant arthritis. Immunology. 1992;77(3):449-455.
28. Grimaldi MG. Long-term low dose haloperidol treatment in rheumatoid patients: effects on serum sulphydryl levels, technetium index, ESR, and clinical response. Br J Clin Pharmacol. 1981;12(4):579-581. (Pubitemid 11059797)
29. Moots RJ, et al. Old drug, new tricks: haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis. 1999;58(9):585-587. (Pubitemid 29409107)
30. Aigner T, et al. Osteoarthritis: pathobiology-targets and ways for therapeutic intervention. Adv Drug Deliv Rev. 2006;58(2):128-149.
31. Adams CS, Horton WE Jr. Chondrocyte apoptosis increases with age in the articular cartilage of adult animals. Anat Rec. 1998;250(4):418-425. (Pubitemid 28180432)
32. Heraud F, Heraud A, Harmand MF. Apoptosis in normal and osteoarthritic human articular cartilage. Ann Rheum Dis. 2000;59(12):959-965.
33. Cho TJ, et al. Tumor necrosis factor alpha activation of the apoptotic cascade in murine articular chondrocytes is associated with the induction of metalloproteinases and specific pro-resorptive factors. Arthritis Rheum. 2003;48(10):2845-2854.
34. Westacott CI, et al. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann Rheum Dis. 1990;49(9):676-681. (Pubitemid 20279117)
35. Schlaak JF, et al. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol. 1996;14(2):155-162. (Pubitemid 26160127)
36. Rohner E, et al. Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases. Immunol Res. 2012;52(3):169-175.
37. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from rodents about prolactin in humans? Endocr Rev. 2008;29(1):1-41. (Pubitemid 351252745)
38. Corbacho AM, et al. Cytokine induction of prolactin receptors mediates prolactin inhibition of nitric oxide synthesis in pulmonary fibroblasts. FEBS Lett. 2003;544(1-3):171-175. (Pubitemid 36628056)
39. Hunter S, Koch BL, Anderson SM. Phosphorylation of cbl after stimulation of Nb2 cells with prolactin and its association with phosphatidylinositol 3-kinase. Mol Endocrinol. 1997;11(9):1213-1222. (Pubitemid 28041329)
40. al-Sakkaf KA, Dobson PR, Brown BL. Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells. J Mol Endocrinol. 1997;19(3):347-350.
41. Bailey JP, et al. Prolactin and transforming growth factor-beta signaling exert opposing effects on mammary gland morphogenesis, involution, and the Akt-forkhead pathway. Mol Endocrinol. 2004;18(5):1171-1184. (Pubitemid 38591283)
42. Tessier C, et al. PRL antiapoptotic effect in the rat decidua involves the PI3K/protein kinase B-mediated inhibition of caspase-3 activity. Endocrinology. 2001;142(9):4086-4094. (Pubitemid 32802681)
43. Price J, et al. Akt-1 mediates survival of chondrocytes from endoplasmic reticulum-induced stress. J Cell Physiol. 2010;222(3):502-508.
44. Chen Q, et al. Increased apoptosis in human knee osteoarthritis cartilage related to the expression of protein kinase B and protein kinase Cα in chondrocytes. Folia Histochem Cytobiol. 2012;50(1):137-143.
45. van Beuningen HM, Arntz OJ, van den Berg WB. In vivo effects of interleukin-1 on articular cartilage. Prolongation of proteoglycan metabolic disturbances in old mice. Arthritis Rheum. 1991;34(5):606-615.
46. Hauselmann HJ, et al. The superficial layer of human articular cartilage is more susceptible to interleukin-1-induced damage than the deeper layers. Arthritis Rheum. 1996;39(3):478-488. (Pubitemid 26085224)
47. Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol. 1998;10(3):263-268. (Pubitemid 28286819)
48. Hashimoto S, et al. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis Rheum. 1998;41(9):1632-1638. (Pubitemid 28459922)
49. Leiderman S, et al. Prolactin and IgG-prolactin complex levels in patients with rheumatic arthritis. Ann N Y Acad Sci. 2002;966:252-257. (Pubitemid 34729182)
50. Clement-Lacroix P, et al. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology. 1999;140(1):96-105. (Pubitemid 29011146)
51. Bendele A. Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact. 2001;1(4):377-385.
52. Spears R, et al. Tumour necrosis factor-alpha and apoptosis in the rat temporomandibular joint. Arch Oral Biol. 2003;48(12):825-834. (Pubitemid 37400044)
53. Gonzalez C, et al. Inflammation, synovial angiogenesis and chondroid apoptosis in the evolution of type II collagen-induced arthritis. Eur Cytokine Netw. 2007;18(3):127-135. (Pubitemid 47573421)
54. Song C, et al. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res. 2000;42(2):157-164. (Pubitemid 30163081)
55. Resman-Targoff BH, Cicero MP. Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. Am J Manag Care. 2010;16(9 suppl):S249-S258.
56. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science. 1999;283(5406):1277-1278. (Pubitemid 129507205)
57. Neidhart M, Gay RE, Gay S. Prolactin and prolactin-like polypeptides in rheumatoid arthritis. Biomed Pharmacother. 1999;53(5-6):218-222.
58. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev. 2007;6(8):537-542. (Pubitemid 47374609)
59. Jara LJ, et al. Prolactin and autoimmunity. Clin Rev Allergy Immunol. 2011;40(1):50-59.
60. Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev. 2012;11(6-7):A465-A470.
61. Zhornitsky S, et al. Prolactin in multiple sclerosis. Mult Scler. 2013;19(1):15-23.
62. Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta Biomed. 2007;78(suppl 1):255-261.
63. Corbacho AM, et al. Human umbilical vein endothelial cells express multiple prolactin isoforms. J Endocrinol. 2000;166(1):53-62. (Pubitemid 30435874)
64. Jacobi AM, et al. Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls. Ann Rheum Dis. 2001;60(3):242-247. (Pubitemid 32260607)
65. Matera L, et al. Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes. Brain Behav Immun. 1992;6(4):409-417. (Pubitemid 23054162)
66. Gerli R, et al. Reduced number of natural killer cells in patients with pathological hyperprolactinemia. Clin Exp Immunol. 1986;64(2):399-406. (Pubitemid 16102168)
67. Vidaller A, et al. Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. J Clin Immunol. 1992;12(3):210-215.
68. Vukusic S, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004;127(pt 6):1353-1360. (Pubitemid 38745513)
69. Mok CC, Wong RW, Lau CS. Exacerbation of systemic lupus erythematosus by breast feeding. Lupus. 1998;7(8):569-570. (Pubitemid 28542637)
70. McMurray RW, et al. Effects of parturition, suckling and pseudopregnancy on variables of disease activity in the B/W mouse model of systemic lupus erythematosus. J Rheumatol. 1993;20(7):1143-1151. (Pubitemid 23278165)
71. Barrett JH, et al. Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum. 2000;43(5):1010-1015. (Pubitemid 30368177)
72. Langer-Gould A, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009;66(8):958-963.
73. McMurray RW. Bromocriptine in rheumatic and autoimmune diseases. Semin Arthritis Rheum. 2001;31(1):21-32. (Pubitemid 32756169)
74. Hardy RS, Raza K, Cooper MS. Endogenous glucocorticoids in inflammation: contributions of systemic and local responses. Swiss Med Wkly. 2012;142:w13650.
75. Horseman ND, et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 1997;16(23):6926-6935. (Pubitemid 27520793)
76. Bouchard B, et al. Immune system development and function in prolactin receptor-deficient mice. J Immunol. 1999;163(2):576-582. (Pubitemid 29328058)
77. Gala RR. The physiology and mechanisms of the stress-induced changes in prolactin secretion in the rat. Life Sci. 1990;46(20):1407-1420. (Pubitemid 20171445)
78. Dorshkind K, Horseman ND. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev. 2000;21(3):292-312. (Pubitemid 32275590)
79. Hamada T, et al. Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor. Br J Pharmacol. 2000;131(8):1513-1520. (Pubitemid 32056414)
80. Tanaka T, et al. A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J Clin Endocrinol Metab. 1980;51(5):1058-1063. (Pubitemid 11225461)